Stockscreener 앱 받기
14.74
0.65%
0.095
전일 마감가:
$14.65
열려 있는:
$14.79
하루 거래량:
78,118
Relative Volume:
0.33
시가총액:
$1.88B
수익:
$7.50M
순이익/손실:
$-81.89M
주가수익비율:
0.2781
EPS:
53.0176
순현금흐름:
$-63.58M
1주 성능:
+34.53%
1개월 성능:
+41.30%
6개월 성능:
-16.13%
1년 성능:
+95.30%
1일 변동 폭
$14.45
$14.90
1주일 범위
$11.05
$16.07
52주 변동 폭
$5.78
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
14.74 | 1.43B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.14 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.43 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.26 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.82 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.00 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-12-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-24 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-23 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 개시 | William Blair | Outperform |
| 2022-12-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-06 | 개시 | Piper Sandler | Overweight |
| 2021-04-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-12-22 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-12-04 | 다운그레이드 | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2020-05-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-31 | 재개 | H.C. Wainwright | Buy |
| 2018-03-22 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-08-31 | 개시 | Oppenheimer | Outperform |
| 2017-06-08 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Mesoblast Ltd Adr 주식(MESO)의 최신 뉴스
Company’s Banking Stock: Dissecting a -4.28% Quarterly Revenue Decline Amid Growth - investchronicle.com
Novagold Resources Inc (NG) Stock: A Year of Decreases and Increases - investchronicle.com
TV’s 2025 Market Dance: Down -20.11% – Time to Invest? - investchronicle.com
Cango Inc ADR (CANG) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Mesoblast Ltd ADR Inc. (MESO) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Innodata Inc (INOD) Stock: A Year of Market Movement, Down and Up - investchronicle.com
BILL Holdings Inc Inc. (BILL) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Burford Capital Limited: Navigating Market Fluctuations with a 3.10B Market Cap - investchronicle.com
Chagee Holdings Ltd. ADR (CHA) Stock: A Year of Highs and Lows - investchronicle.com
Nano X Imaging Ltd (NNOX) Stock: The Story of a 52-Week Stock Range - investchronicle.com
LU’s Stock Dilemma: Lufax Holding Ltd ADR’s Market Performance and Outlook - investchronicle.com
ZTO’s Stock Market Adventure: -5.37% YTD Growth Amidst Volatility - investchronicle.com
MGRX’s Market Whiplash: -74.88% YTD Decline, -16.49% Plunge in 30 Days - investchronicle.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com India
Sonim Technologies Inc (SONM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Successful Commercial Launch of Ryoncil® - GlobeNewswire Inc.
An In-Depth Look at Trident Digital Tech Holdings Ltd. ADR Inc. (TDTH) Price Performance During Market Crashes - investchronicle.com
BTCM: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Perspective Therapeutics Inc (CATX Stock: A Sea of Opportunity - investchronicle.com
DallasNews Corporation (DALN) Stock: Uncovering 52-Week Market Trends - investchronicle.com
DraftKings Inc (DKNG) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
TSM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
GE Vernova Inc (GEV) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
All Markets & Instruments Available to Trade - Capital.com
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil® - thecapitalclub.com.au
UPDATED: Your guide to February Reporting Season 2020 - Morningstar.com.au
21 Best-Performing Small-Cap Stocks for March 2025 - NerdWallet
Why Mesoblast Ltd ADR (NASDAQ: MESO) Is Worth Including On Your Watchlist - Marketing Sentinel
The 98.76% Simple Moving Average of Mesoblast Ltd ADR’s (MESO) Stock in the Past 200 Days - The News Heater
Mesoblast Ltd ADR (NASDAQ:MESO) Shares Are Up 10.24 Percent In A Week – But Can The Gains Continue? - Marketing Sentinel
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
Mesoblast (NASDAQ:MESO) Shares Gap UpWhat's Next? - MarketBeat
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Mesoblast shares downgraded to hold by Jefferies By Investing.com - Investing.com South Africa
Why the Mesoblast share price is diving 18% after an FDA win - The Motley Fool Australia
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast to raise $50m from top shareholder for product launch - Capital Brief
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - TradingView
11 Best ASX Stocks To Buy Now - Yahoo Finance
Mesoblast Ltd Adr (MESO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
0.13%
자본화:
|
볼륨(24시간):